KCNJ4变种破坏了向内调整器通道功能,并导致耐火性
Hu Pan1,2, Deng Liu3, Wuhen Xu4
1Key Laboratory for Birth Defects Research and Prevention of the National Health Commission, Affiliated Maternal and Child Health Care Hospital, Hengyang Medical School, University of South China (Hunan Provincial Maternal and Child Health Care Hospital), Changsha City, China.
Epilepsia
|March 14, 2026
概括
这项研究确定了与有关的KCNJ4基因变异,揭示了增加和减少的内向整顿通道功能对神经障碍有所贡献.
科学领域:
- 神经遗传学 神经遗传学
- 分子生物学分子生物学
- 道病变是一种通道病变.
背景情况:
- 是一种常见的神经疾病,具有重要的遗传成分,通常涉及离子通道功能障碍.
- 内向整形 (Kir) 通道与发生有关,但KCNJ4在人类中的作用以前尚未确定.
研究的目的:
- 在耐火性患者中识别致病性KCNJ4变异.
- 功能性地描述已识别的KCNJ4变异及其对Kir2.3通道活动的影响.
主要方法:
- 整体外基因组测序用于识别四个无关个体中的KCNJ4变异.
- 在Xenopus卵细胞中的两电极电压记录评估了变异的功能后果.
- 西方斑点分析检查了蛋白质表达水平,以排除贩运或表达文物.
主要成果:
- 鉴定出了四种罕见的异合体的KCNJ4误解变异 (Gly136Ser,Val206Met,Met293Lys,Glu384Lys).
- 两种变体 (Gly136Ser,Glu384Lys) 显示功能增强,增加电流.
- 两个变体 (Val206Met,Met293Lys) 显示功能丧失,减少电流,独立于表达水平.
结论:
- 鉴定KCNJ4是一种与相关的新型基因.
- 基尔2.3通道的功能的增加和丧失机制都会导致发.
- 这扩大了对的遗传理解,并突出了针对基尔通道功能的治疗潜力.
相关概念视频
Antiepileptic Drugs: Potassium Channel Activators
895
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
895
Antiepileptic Drugs: Calcium Channel Blockers
1.5K
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
1.5K
Antiepileptic Drugs: Sodium Channel Blockers
2.1K
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
2.1K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
1.1K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.1K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
2.5K
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
2.5K
Voltage-gated Ion Channels
12.5K
Voltage-gated ion channels are transmembrane proteins that open and close in response to changes in the membrane potential. They are present on the membranes of all electrically excitable cells such as neurons, heart, and muscle cells.
Generally, all voltage-gated ion channels have a 'voltage-sensing domain' that spans the lipid bilayer. The charged residues in the sensor move in response to the membrane potential changes that open the channel allowing ions movement. There are several types of...
Generally, all voltage-gated ion channels have a 'voltage-sensing domain' that spans the lipid bilayer. The charged residues in the sensor move in response to the membrane potential changes that open the channel allowing ions movement. There are several types of...
12.5K


